A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Summus Raises $19.5 Million

To expand solutions solving the access problem in specialty care

Summus, the leading virtual health company focused in specialty care, announced today that it raised $19.5 million to support the company’s continued growth and work to solve the access problem to high quality physicians. Following a previous investment round in 2022, Summus has now raised $70 million to expand its innovative approach to care.

The company’s proprietary marketplace model empowers patients, families, caregivers and physicians to share and access high quality specialty expertise — across all health questions, at any point in the journey. By accelerating access to high quality physicians, Summus delivers best-in-class clinical guidance, advocacy and navigation. Summus works with leading employers, health plans, physician groups and leading medical institutions to provide a broad portfolio of solutions that improves access to quality care and improves outcomes.

“Durable, category defining companies naturally evolve and expand their aperture to serve more people over time. We are investing to meet the explosive demand for Summus solutions across the healthcare ecosystem,” said Mitchell Rales, Co-founder and Executive Chairman, Danaher Corporation.

In supporting more than 2 million lives, 98% of Summus members report that they better understand what to do in the next stage of their healthcare journey. Since 2020, consistent feedback from Summus members and physicians reflect universal recognition of the access and insights through Summus that would not otherwise have been available.

“The value of accessing high quality physicians in an expedient manner is vital — for peace of mind, optimizing treatment paths, and driving better outcomes. We continue our commitment to put high quality physicians, the most trusted party in healthcare, at the center of decisions big and small,” said Julian Flannery, Summus CEO and Co-founder.

The investment will focus on further scaling growth for the organization, including meeting demand for Summus’ innovative solution to support primary care physicians in a peer-to-peer environment, and enhancing condition-specific, personalized journeys for patients to access the best care with the most trusted physicians.

“We remain inspired by the Summus team and the value proposition they bring to the healthcare ecosystem. In providing access to thousands of the world’s most talented physicians to patients, families and physicians who need their expertise, we see Summus changing lives on a daily basis. We’re grateful to have the opportunity to continue to support Summus as they expand their capabilities to solve the critical issues of access to quality healthcare today,” said Rick Buhrman, Co-Founder and Co-CEO, Sator Grove Holdings. “I am impressed by the continued innovation, commitment and expertise of the Summus team, and am thrilled to see their growth and recognition in the market for bringing new solutions to physicians and patients around the world.”

SourceSummus
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.
The investment will allow ROM InWest to further distribute its fall detection product globally.
Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”
Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). Obsidian Therapeutics is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.

By using this website you agree to accept Medical Device News Magazine Privacy Policy